# IDYA catalysts: IDEAYA Biosciences, Inc. PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/idya/catalysts

> IDEAYA Biosciences, Inc. (IDYA) has 8 upcoming catalysts. The next is the IDE034 interim data readout, 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, half-year only, exact day, quarter only, year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What are the upcoming FDA catalysts for IDYA?

IDEAYA Biosciences, Inc. (IDYA) has 8 upcoming catalysts. The next is the IDE034 interim data readout, 2027. Press release filed with the SEC (EX-99): "IDE034 (B7H3/PTK7 bispecific TOP1 ADC): IDEAYA plans to provide initial clinical data from its ongoing Phase 1 dose escalation trial in 2027, which is expected to include preliminary safety and efficacy data." [Calendar and source filings](https://sec-api.dev/companies/idya/catalysts)

Source: Press release filed with the SEC (EX-99), accession 0001193125-26-444225, https://www.sec.gov/Archives/edgar/data/1676725/000119312526444225/idya-ex99_1.htm (retrieved 2026-11-12). Last confirmed 2026-11-03. Cite: https://sec-api.dev/companies/idya/catalysts#answer

## Company

| Field | Value |
| --- | --- |
| Name | IDEAYA Biosciences, Inc. |
| Ticker | IDYA (Nasdaq) |
| SEC CIK | 1676725 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/idya |

## Cash runway

Cash $1.15B as of 2026-09-30; quarterly burn $93.5M; about 36.9 months of runway at that rate (XBRL company facts, accession 0001193125-26-445294).

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Oct 2024 | [IDE275 trial start](https://sec-api.dev/pdufa/ide275) | IDYA | MSI-High tumors pursuant | completed | "In October 2024, GSK initiated a Phase 1 clinical trial with IDE275 in patients with MSI-High tumors pursuant to our 2020 Collaboration, Option and License Agreement." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1676725/000119312526054533/idya-20251231.htm)) |
| Dec 2024 | [IDE161 trial start](https://sec-api.dev/pdufa/ide161) | IDYA |  | completed | "In December 2024, the first patient was dosed with IDE161 in combination with KEYTRUDA in the Company-sponsored Phase 1 clinical trial." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1676725/000095017025064438/idya-20250331.htm)) |
| 1H 2025 | [Darovasertib trial start](https://sec-api.dev/pdufa/darovasertib) | IDYA |  | scheduled | "Commencement of the Phase 3 registration-enabling trial for darovasertib in neoadjuvant UM is targeted for the first half of 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1676725/000095017025063938/idya-ex99_1.htm)) |
| February 13, 2025 | [IDEAYA Biosciences, Inc. earnings report](https://sec-api.dev/companies/idya/catalysts) | IDYA |  | completed | "IDEAYA Biosciences, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1676725/000095017025019314/idya-ex99_1.htm)) |
| Apr 2025 | [Darovasertib trial start](https://sec-api.dev/pdufa/darovasertib) | IDYA |  | completed | "Following a successful Type D meeting with the FDA in April 2025, the company initiated a randomized Phase 3 registration-enabling trial of darovasertib in the neoadjuvant setting for primary UM in the third quarter of 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1676725/000095017025102353/idya-ex99_1.htm)) |
| May 6, 2025 | [IDEAYA Biosciences, Inc. earnings report](https://sec-api.dev/companies/idya/catalysts) | IDYA |  | completed | "IDEAYA Biosciences, Inc. Reports First Quarter 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1676725/000095017025063938/idya-ex99_1.htm)) |
| August 5, 2025 | [IDEAYA Biosciences, Inc. earnings report](https://sec-api.dev/companies/idya/catalysts) | IDYA |  | completed | "IDEAYA Biosciences, Inc. Reports Second Quarter 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1676725/000095017025102353/idya-ex99_1.htm)) |
| late 2025 | [IDE849 trial start](https://sec-api.dev/pdufa/ide849) | IDYA |  | scheduled | "IDEAYA plans to initiate a Phase 1 combination trial of IDE849 and IDE161 by the end of 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1676725/000119312525263383/idya-ex99_1.htm)) |
| late 2025 | [IDEAYA Biosciences, Inc. topline data readout](https://sec-api.dev/companies/idya/catalysts) | IDYA |  | scheduled | "Over 230 patients enrolled in potential registration-enabling trial in 1L HLA-A2-negative MUM, and median PFS readout targeted by year-end 2025" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1676725/000095017025019314/idya-ex99_1.htm)) |
| late 2025 | [IDE397 trial start](https://sec-api.dev/pdufa/ide397) | IDYA |  | scheduled | "IDEAYA received IND clearance from the FDA in the third quarter and expects to begin a Phase 1 dose escalation trial by the end of the year with the goal of advancing into combination trials with IDE397 in the first half of 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1676725/000119312525263383/idya-ex99_1.htm)) |
| late 2025 | [Darovasertib topline data readout](https://sec-api.dev/pdufa/darovasertib) | IDYA |  | scheduled | "Phase 2 median overall survival (OS) readout from study IDE196-001 in over 40 1L MUM patients targeted at a medical conference in the second half of 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1676725/000095017025063938/idya-ex99_1.htm)) |
| September 8, 2025 | [Darovasertib interim data readout](https://sec-api.dev/pdufa/darovasertib) | IDYA |  | completed, positive | "On September 8, 2025, the Company presented positive interim data at their 10-Year Anniversary R&D Day from its ongoing Phase 2 OptimUM-09 trial of darovasertib in the neoadjuvant setting for primary uveal melanoma ("UM")." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1676725/000119312525197605/d38716d8k.htm)) |
| November 4, 2025 | [IDEAYA Biosciences, Inc. earnings report](https://sec-api.dev/companies/idya/catalysts) | IDYA |  | completed | "IDEAYA Biosciences Reports Third Quarter 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1676725/000119312525263383/idya-ex99_1.htm)) |
| Q1 2026 | [IDE574 trial start](https://sec-api.dev/pdufa/ide574) | IDYA | breast, lung, prostate and colorectal cancers Q1 '26 | scheduled | "IDE574 (KAT6/7): obtained IND clearance from the U.S. FDA in January 2026; targeting to initiate a Phase 1 dose escalation trial in patients with breast, lung, prostate and colorectal cancers Q1 '26." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1676725/000119312526052741/idya-ex99_1.htm)) |
| Q1 2026 | [Darovasertib topline data readout](https://sec-api.dev/pdufa/darovasertib) | IDYA |  | scheduled | "We are targeting to report topline results from the darovasertib and crizotinib combination in our registrational Phase 2/3 OptimUM-02 trial in 1L patients with HLA*A2(-) mUM in the first quarter of 2026." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1676725/000119312526054533/idya-20251231.htm)) |
| 1H 2026 | [Darovasertib trial start](https://sec-api.dev/pdufa/darovasertib) | IDYA |  | scheduled | "In collaboration with Servier, IDEAYA plans to initiate a global Phase 3 combination trial of darovasertib and crizotinib as an adjuvant therapy for primary UM in the first half of 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1676725/000119312525263383/idya-ex99_1.htm)) |
| February 17, 2026 | [IDEAYA Biosciences, Inc. earnings report](https://sec-api.dev/companies/idya/catalysts) | IDYA |  | completed | "IDEAYA Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1676725/000119312526052741/idya-ex99_1.htm)) |
| Q2 2026 | [IDE161 trial start](https://sec-api.dev/pdufa/ide161) | IDYA |  | scheduled | "Pending ongoing dose-finding work, we are targeting to initiate a Phase 1 clinical combination trial with IDE161 and IDE849 (DLL3) in SCLC, NEC and potentially other DLL3-overexpressing solid tumors in the second quarter of 2026." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1676725/000119312526054533/idya-20251231.htm)) |
| Q2 2026 | [IDE849 trial start](https://sec-api.dev/pdufa/ide849) | IDYA |  | scheduled | "We are also targeting to initiate a Phase 1 clinical combination trial with IDE849 and IDE161, our proprietary PARG inhibitor, in the second quarter of 2026." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1676725/000119312526054533/idya-20251231.htm)) |
| Apr 2026 | [IDEAYA Biosciences, Inc. topline data readout](https://sec-api.dev/companies/idya/catalysts) | IDYA |  | completed, met | "In April 2026, we reported positive topline data from the OptimUM-02, which met its primary endpoint demonstrating as statistically significant improvement in median progression free survival as assessed by blinded independent central review." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1676725/000119312526332774/idya-20260630.htm)) |
| May 5, 2026 | [IDEAYA Biosciences, Inc. earnings report](https://sec-api.dev/companies/idya/catalysts) | IDYA |  | completed | "IDEAYA Biosciences Reports First Quarter 2026 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1676725/000119312526204944/idya-ex99_1.htm)) |
| 2H 2026 | [IDE892 trial start](https://sec-api.dev/pdufa/ide892) | IDYA |  | scheduled | "Announced clinical collaboration with Roche to evaluate IDE892 (PRMT5) in combination with RG6505 (pan-RAS) in MTAP-deleted, RAS-mutant pancreatic cancer; targeting to initiate a Phase 1 combination trial in H2 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1676725/000119312526331381/idya-ex99_1.htm)) |
| 2H 2026 | [Darovasertib NDA/BLA submission](https://sec-api.dev/pdufa/darovasertib) | IDYA |  | scheduled | "Based on these data, the Company will target to submit an NDA to the U.S. Food and Drug Administration ("FDA") in the second half of 2026." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1676725/000119312526151893/d114952d8k.htm)) |
| August 4, 2026 | [IDEAYA Biosciences, Inc. earnings report](https://sec-api.dev/companies/idya/catalysts) | IDYA |  | completed | "IDEAYA Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1676725/000119312526331381/idya-ex99_1.htm)) |
| late 2026 | [IDE849 trial start](https://sec-api.dev/pdufa/ide849) | IDYA |  | scheduled | "IDEAYA's China-region partner, Jinagsu Hengrui Pharmaceuticals Co. Ltd., is targeting to initiate Phase 3 registrational trials in China in 2027 for IDE849 in SCLC and provide a clinical update from their Phase 1 trial in SCLC and NEC at a medical conference in the second half of 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1676725/000119312526204944/idya-ex99_1.htm)) |
| late 2026 | [IDE034 interim data readout](https://sec-api.dev/pdufa/ide034) | IDYA |  | scheduled | "IDE034 (B7H3/PTK7 bispecific TOP1 ADC): IDEAYA plans to provide initial clinical data from its ongoing Phase 1 dose escalation trial by the end of 2026 or early 2027, which is expected to include preliminary safety and efficacy data." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1676725/000119312526331381/idya-ex99_1.htm)) |
| November 3, 2026 | [IDEAYA Biosciences, Inc. earnings report](https://sec-api.dev/companies/idya/catalysts) | IDYA |  | completed | "IDEAYA Biosciences Reports Financial Results for the Third Quarter 2026 and Provides a Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1676725/000119312526444225/idya-ex99_1.htm)) |
| 2027 | [IDE034 interim data readout](https://sec-api.dev/pdufa/ide034) | IDYA |  | scheduled | "IDE034 (B7H3/PTK7 bispecific TOP1 ADC): IDEAYA plans to provide initial clinical data from its ongoing Phase 1 dose escalation trial in 2027, which is expected to include preliminary safety and efficacy data." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1676725/000119312526444225/idya-ex99_1.htm)) |
| Jan to Apr 2027 | [Darovasertib topline data readout](https://sec-api.dev/pdufa/darovasertib) | IDYA | Metastatic Uveal Melanoma | scheduled | "NCT05987332 (IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2027-01-15 (ESTIMATED); Lead Sponsor IDEAYA Biosciences." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05987332)) |
| January 2027 | [Darovasertib primary completion](https://sec-api.dev/pdufa/darovasertib) | IDYA | Metastatic Uveal Melanoma | scheduled | "NCT05987332 (IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2027-01-15 (ESTIMATED); Lead Sponsor IDEAYA Biosciences." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05987332)) |
| mid-2027 | [Darovasertib interim data readout](https://sec-api.dev/pdufa/darovasertib) | IDYA |  | scheduled | "IDEAYA plans to provide an update on the OS data as part of the pre-specified interim analysis expected in mid-2027." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1676725/000119312526331381/idya-ex99_1.htm)) |
| Apr to Jul 2027 | [Darovasertib topline data readout](https://sec-api.dev/pdufa/darovasertib) | IDYA | Uveal Melanoma | scheduled | "NCT05907954 ((Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-04-30 (ESTIMATED); Lead Sponsor IDEAYA Biosciences." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05907954)) |
| April 2027 | [Darovasertib primary completion](https://sec-api.dev/pdufa/darovasertib) | IDYA | Uveal Melanoma | scheduled | "NCT05907954 ((Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-04-30 (ESTIMATED); Lead Sponsor IDEAYA Biosciences." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05907954)) |
| October 2030 | [Darovasertib primary completion](https://sec-api.dev/pdufa/darovasertib) | IDYA | Uveal Melanoma | scheduled | "NCT07015190 (Neoadjuvant Darovasertib in Primary Uveal Melanoma): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-10 (ESTIMATED); Lead Sponsor IDEAYA Biosciences." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07015190)) |
| Oct 2030 to Jan 2031 | [Darovasertib topline data readout](https://sec-api.dev/pdufa/darovasertib) | IDYA | Uveal Melanoma | scheduled | "NCT07015190 (Neoadjuvant Darovasertib in Primary Uveal Melanoma): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-10 (ESTIMATED); Lead Sponsor IDEAYA Biosciences." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07015190)) |

## Drugs

- [Darovasertib](https://sec-api.dev/pdufa/darovasertib): Metastatic Uveal Melanoma, Uveal Melanoma
- [IDE034](https://sec-api.dev/pdufa/ide034): 
- [IDE161](https://sec-api.dev/pdufa/ide161): 
- [IDE275](https://sec-api.dev/pdufa/ide275): msi-high tumors pursuant
- [IDE397](https://sec-api.dev/pdufa/ide397): 
- [IDE574](https://sec-api.dev/pdufa/ide574): breast, lung, prostate and colorectal cancers q1 '26
- [IDE849](https://sec-api.dev/pdufa/ide849): 
- [IDE892](https://sec-api.dev/pdufa/ide892): 

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/idya/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "IDYA catalysts: IDEAYA Biosciences, Inc. PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/idya/catalysts

```bibtex
@misc{secapidev_companies_idya_catalysts_20261116,
  title        = {IDYA catalysts: IDEAYA Biosciences, Inc. PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/idya/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_idya_catalysts_20261116","title":"IDYA catalysts: IDEAYA Biosciences, Inc. PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/idya/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
